Journal
HUMAN IMMUNOLOGY
Volume 79, Issue 5, Pages 294-303Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.humimm.2017.12.013
Keywords
Regulatory T cells; T cell; Tolerance; Immunosuppression; Humanized mouse
Categories
Funding
- European Union FP7
- UK Medical Research Council
- Kidney Research UK
- European Society for Organ Transplantation
- Restore Research Trust
- Academy of Medical Sciences (AMS) [AMS-SGCL11-Issa] Funding Source: researchfish
- Medical Research Council [MR/N027930/1] Funding Source: researchfish
- National Institute for Health Research [CL-2013-13-005] Funding Source: researchfish
- MRC [MR/N027930/1] Funding Source: UKRI
Ask authors/readers for more resources
Regulatory T cells (Tregs) are critical mediators of immune homeostasis and hold significant promise in the quest for transplantation tolerance. Progress has now reached a critical threshold as techniques for production of clinical therapies are optimised and Phase I/II clinical trials are in full swing. Initial safety and efficacy data are being reported, with trials assessing a number of different strategies for the introduction of Treg therapy. It is now more crucial than ever to elucidate further the function and behaviour of Tregs in vivo and ensure safe delivery. This review will discuss the current state of the art and future directions in Treg therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available